Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. (Q37823790)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jean-Yves Blay

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

M Van Glabbeke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

S Marreaud

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

M Ouali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

P Hohenberger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

23 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1266-1272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21183581%20AND%20SRC:MED&resulttype=core&format=json

Soft-tissue sarcomas in adults

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Novel designs and end points for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Publication biases and phase II trials investigating anticancer targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Other endpoints in screening studies for soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608

Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ608